An ongoing randomized controlled trial is investigating whether 2,000 mg daily ginger extract can alleviate chronic sciatica by modulating the gut-brain axis over eight weeks. The study tracks 80 participants stratified by BMI, measuring pain outcomes alongside brain connectivity changes using fMRI and diffusion tensor imaging, plus gut microbiome composition through 16S rRNA sequencing and neuroinflammation markers. This represents a sophisticated mechanistic approach to understanding how dietary anti-inflammatory compounds might treat neuropathic pain. The gut-brain axis has emerged as a critical pathway in chronic pain conditions, with mounting evidence that intestinal permeability and microbiome dysbiosis contribute to neuroinflammation. Ginger's bioactive compounds, particularly gingerols and shogaols, possess well-documented anti-inflammatory properties that could theoretically interrupt this cascade. However, this remains a study protocol rather than completed research with results. The 2,000 mg daily dose is substantially higher than typical culinary amounts, raising questions about tolerability and optimal dosing. While the multimodal assessment approach is methodologically sound, the eight-week intervention period may be insufficient to detect meaningful microbiome changes or sustained neuroplasticity adaptations in chronic pain conditions.